Currently, the best therapeutic option for progressive hepatocellular carcinoma is a combination of programmed death-ligand 1(PDL1) blockers and vascular endothelial growth factor(VEGF) antagonists, whereas chemotherapy remains the best alternative for intrahepatic cholangiocarcinoma [4]. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.